LenioBio Secures €3.7 Million EU4Health Grant for Advancing Protein-Based Medicine Production
Berlin, Germany – July 23, 2025 – LenioBio, a pioneering company dedicated to revolutionizing biopharmaceutical manufacturing, is pleased to announce it has been awarded a significant grant of €3.7 million from the EU4Health program. This funding will be instrumental in further developing LenioBio’s innovative ALiCE® platform, designed to facilitate the cost-effective and rapid production of protein-based medicines.
The EU4Health program, a key initiative by the European Union, aims to strengthen health systems and improve the health and well-being of citizens across the continent. This substantial grant underscores the EU’s commitment to fostering cutting-edge solutions that can address critical healthcare needs and enhance the accessibility of advanced therapeutics.
LenioBio’s ALiCE® platform represents a breakthrough in bioprocessing technology. It offers a novel approach to producing therapeutic proteins, which are a crucial component of many modern medicines, including treatments for cancer, autoimmune diseases, and rare genetic disorders. Traditional methods for producing these complex molecules can be time-consuming and expensive, often creating bottlenecks in the supply chain and impacting the affordability and availability of life-saving treatments.
The ALiCE® platform is engineered to overcome these challenges by providing a faster, more efficient, and cost-effective manufacturing process. This innovative system has the potential to significantly reduce the production costs of protein-based drugs, making them more accessible to patients and healthcare systems alike. Furthermore, the enhanced speed of production can accelerate the delivery of vital therapies to those in need, particularly during public health emergencies.
“We are incredibly honored to receive this prestigious EU4Health grant,” said [Insert Name and Title of LenioBio Spokesperson, if available]. “This funding is a strong validation of our ALiCE® technology and its potential to transform the landscape of biopharmaceutical manufacturing. It will enable us to accelerate the optimization and scaling of our platform, ultimately contributing to the wider availability of essential protein-based medicines across Europe and beyond.”
The grant will support several key areas of development for LenioBio, including further research and development to enhance the ALiCE® platform’s capabilities, expansion of manufacturing capacity, and the establishment of strategic partnerships within the European health ecosystem. By leveraging this funding, LenioBio aims to solidify its position as a leader in next-generation biomanufacturing solutions.
This investment from the EU4Health program is expected to have a profound impact on the pharmaceutical industry, paving the way for more sustainable and accessible production of critical protein-based therapeutics. LenioBio is dedicated to working closely with European health authorities and industry stakeholders to realize the full potential of the ALiCE® platform in improving public health.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘LenioBio erhält EU4Health-Förderung in Höhe von 3,7 Mio. EUR für die Entwicklung von ALiCE® zur kostengünstigen und schnellen Herstellung von Medikamenten auf Proteinbasis’ at 2025-07-23 07:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.